Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, Obinutuzumab, and Venetoclax in CLL, SLL, and Richter Transformation
NCT02846623Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2017
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and Richter syndrome (RS) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Minimal residual disease negative rate. Started Jan 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT02846623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846623.